drugset / Trial / NCT01639846

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846 ↗

Phase 2 Completed 60 enrolled C.T. Development America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject NAVAMEPENT Small molecule 0.09 % Other

Indications